A recent study suggests that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional lifestyle regimens.
Research printed in a prominent medical journal demonstrates that while overweight individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People buying these medications must be cognizant of the danger of rapid rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass in about 18 months.
Analyzing Treatments
The analysis, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists emphasize that people who lose weight through lifestyle changes alone usually have a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Doctors suggest the mode of action of the jabs accounts for the amplified rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Disease?
Medical guidelines suggest the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the persistent nature of obesity," akin to managing diseases like diabetes.
User Testimonies
People who have discontinued the medication explain a intense return of hunger.
"It was like something flipping and you become ravenous," described one woman.
The struggle is worsened if patients have not established sustainable lifestyle or habit changes during treatment.
Growing Interest
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on combined behavioural management.
